Sancilio & Company Introduces New Chief Legal Officer and VP of Strategic Development
Palm Beach County, FL (PRWEB) May 06, 2014 -- Sancilio & Company (SCI), a biopharmaceutical company that specializes in the development of preventative, natural pharmaceuticals, has announced the addition of Dr. John D. Peabody to their management team. Dr. Peabody joins SCI as Chief Legal Officer and Vice President of Strategic Development. He comes to the company after spending almost 15 years as Associate General Counsel of Intellectual Property at ViroPharma Incorporated of Exton, Pennsylvania, now Shire. Prior to that, Peabody was a patent attorney for Novartis, servicing the agrochemical business in Greensboro, North Carolina. He was also employed at the United States Patent and Trademark Office.
Peabody obtained his law degree from George Mason University in 1997. He also has a Ph.D. in Organic Chemistry from the University of New Hampshire and a B.S. in Biochemistry from Trinity College in Hartford, Connecticut. He comes to SCI as a member of The American Intellectual Property Law Association, The American Bar Association, The American Chemical Society and the American Society for Microbiology.
What drew him to the position at SCI? “It was the innovation surrounding pharmaceutical grade natural products.” Peabody said. “These are cost effective, natural products that deliver real solutions to patients. I am excited to capture and leverage related intellectual property assets efficiently to support superior products that can be developed and made right here in the US. I am particularly interested in helping to deliver clear value propositions to patients, employees and investors.”
About Sancilio & Company
Sancilio & Company is an industry leader in Advanced Lipid Technology. It is dedicated to using this technology to develop, manufacture and distribute superior health maintenance and disease preventive products for the benefit of American consumers. Every product in its Ocean Blue® omega-3 fatty acids supplement line is manufactured at its cGMP facility in Riviera Beach, Florida using its unique molecular distillation process to ensure purity, concentrated dosages and less odor. Their website may be viewed at http://www.sancilio.com.
Chad Harrell, Vice President, Commercial Operations, Sancilio & Company, Inc., http://sancilio.com, +1 (561) 899-4113, [email protected]
Share this article